All In MedTech

Device Trial Radar · NCT07135440

The Potential of Optical Coherence Tomography Angiography (OCTA) to Detect Early Cognitive Dysfunction in Diabetic Patients

The Association of Biomarkers Detected by Optical Coherence Tomography Angiography (OCTA) of the Macula With Cognitive Functions in Patients With Type 2 Diabetes

Last checked: Nov 19, 2026Latest source record: Aug 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

210

Planned (sponsor's estimate)

Start

Nov 1, 2024

Primary completion

Oct 30, 2025

Study completion Dec 31, 2025

Sponsor

Lead sponsor
Dr. Sefic Eye Polylcinic and Optical StudioAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 22, 2025

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Diabetic Retinopathy (DR) is one of the most common complications of diabetes, and its association with cognitive dysfunctions is becoming an increasingly frequent research interest. Non-proliferative diabetic retinopathy (NPDR) encompasses early changes at the microvascular level, which can be detected quantitatively and qualitatively through optical coherence tomography angiography (OCTA) well before the first symptoms of this disease appear. Cognitive dysfunction is often unrecognized in the early stages of diabetes. This research will focus on examining the association between OCTA parameters and cognitive functions in patients with NPDR. The aim of this study is to investigate the correlation between OCTA parameters and cognitive functions in patients with NPDR using the Montreal Cognitive Assessment (MoCA) scale to assess cognitive abilities and to establish a connection between OCTA biomarkers and changes in cognitive function. Patients with type 2 diabetes will be included in the study. Patients with proliferations and diabetic macular edema affecting the center and reducing visual acuity will be excluded to minimize error in cognitive function assessment caused by vision impairment. OCTA will be used to analyze microvascular changes in the retina, including capillary density and areas of the avascular zone. At the same time, the MoCA scale will be used to assess cognitive function, focusing on aspects of memory, attention, executive function, and orientation. Data analysis will investigate correlations between OCTA parameters, the presence of diabetic retinopathy-related changes in the eye fundus, as well as the stage of retinopathy and MoCA scale scores, taking into account factors such as diabetes duration, previous diabetes treatment, lipid status, anthropometric parameters, and glycemic control. The results of this research are expected to provide better insight into the early diagnosis of cognitive dysfunctions in patients with diabetes, thereby contributing to the development of targeted interventions.

Conditions

  • Type 2 Diabetes Mellitus Diabetic Retinopathy Cognitive Dysfunction

Interventions

  • OCT angiography RTVue XR Avanti; Optovue, Inc, Fremont, California, USADevice

    OCTA is a fast, non-invasive, and contactless imaging technique that enables detailed visualization of the retinal microvasculature by tracking erythrocyte movement within blood vessels in real time. It provides layer-by-layer analysis of the retina and choroid without the need for intravenous contrast, significantly reducing patient risk and improving accessibility. Increasing evidence suggests that neurodegenerative and vascular changes precede clinically visible signs of disease, making OCTA a valuable diagnostic tool for early detection of diabetic retinopathy before it can be confirmed through standard fundus examination. The MoCA test includes assessments of executive functions, high-level language abilities, and complex visuospatial tasks, making it suitable for detecting even mild cognitive dysfunction.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Quantitative retinal microcirculation parameters detected on OCTATime frame: Day 1

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • dr Sefic Eye Polyclinic and Optical Studio

    Sarajevo, Bosnia and Herzegovina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.